Jeffrey Yoshida, MD
Newport Beach, CA 92663
Jeffrey Yoshida, MD
- Surgical Oncology, Urologic Oncology, Urology
- Hoag Affiliated Physicians
- Hoag Physician Partners
About Jeffrey Yoshida, MD
Jeffrey Yoshida, M.D., is program director of urologic oncology at Hoag Family Cancer Institute and the Benjamin & Carmela Du Endowed Chair in Urologic Oncology. As program director, he plays a key role in the growth of site-specific programs for urologic malignancies, which include prostate, kidney, bladder and testicular cancers.
Dr. Yoshida is an expert in robotic surgery, having performed over 3,000 surgeries to date. He has extensive experience in robotic-assisted radical prostatectomy (prostate removal), radical nephrectomy (kidney removal) and partial nephrectomy. With his knowledge and experience in robotic surgery, Dr. Yoshida brought robotic surgery to Hoag in 2008 and continues to expand Hoag’s capabilities in minimally invasive robotic surgery. Dr. Yoshida has a special interest in prostate cancer and has focused on the development of a comprehensive, multidisciplinary prostate cancer program. Under his leadership, Hoag participated in the institution’s first vaccine clinical trial for low-risk prostate cancer. He also started a prostate cancer early detection program for high-risk men as well as a state-of-the-art active surveillance program for low-risk cancers. He chairs the multidisciplinary prostate/urologic oncology case conferences that are held once a month at Hoag Family Cancer Institute.
Dr. Yoshida is board-certified in urology and has practiced as a urologic oncologist since 2004. He received his undergraduate degree in biology from Pacific Union College and earned his medical degree from Loma Linda University. He completed an internship in general surgery at Harbor-UCLA and a residency in urology at Loma Linda University. Dr. Yoshida then completed a fellowship in urologic oncology/robotic surgery at City of Hope Medical Center. While at City of Hope, he served as assistant clinical professor in the department of urologic oncology and also held a surgical leadership role in the kidney cancer program.